Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Ziihera: unresectable metastatic Biliary tract cancer with HER2 positive

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test

Broader topic: Malignant Biliary Tract Neoplasm

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
unresectable
Biomarkers, prior therapy and derivation
molecular
  1. gene
    HER2
    alteration
    positive
    status
    present
prior therapy
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for Ziihera (zanidatamab-hrii) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
    source wording
    Treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test

    Study evidence for this setting

    1 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT04579380 · Source cited / selected · Scope: unclear

    Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

    6 outcome links · 9 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice